Literature DB >> 19836386

Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function.

Camilo Rojas1, Ajit G Thomas, Jesse Alt, Marigo Stathis, Jie Zhang, Edward B Rubenstein, Silvia Sebastiani, Sergio Cantoreggi, Barbara S Slusher.   

Abstract

Palonosetron is a 5-HT(3) receptor antagonist that has demonstrated superiority in preventing both acute and delayed emesis when compared to older first generation 5-HT(3) receptor antagonists. The objective of this work was to determine if palonosetron exhibits unique molecular interactions with the 5-HT(3) receptor that could provide a scientific rationale for observed clinical efficacy differences. Previously, we showed that palonosetron exhibits allosteric binding and positive cooperativity to the 5-HT(3) receptor in contrast to ondansetron and granisetron which exhibit simple bimolecular binding. The present work shows, through several independent experiments, that palonosetron uniquely triggers 5-HT(3) receptor internalization and induces prolonged inhibition of receptor function. After 24h incubation followed by dissociation conditions, [(3)H]palonosetron remained associated with whole cells but not to cell-free membranes (P<0.001). [(3)H]Palonosetron's binding to cells was resistant to both protease and acid treatments designed to denature cell surface proteins suggesting that the receptor complex was inside the cells rather than at the surface. Cells pretreated with unlabeled palonosetron subsequently exhibited reduced cell surface 5-HT(3) receptor binding. Palonosetron-triggered receptor internalization was visualized by confocal fluorescence microscopy using cells transfected with 5-HT(3) receptor fused to enhanced cyan fluorescent protein. In contrast, granisetron and ondansetron showed minimal to no effect on receptor internalization or prolonged inhibition of receptor function. These experiments may provide a pharmacological basis for differences noted in published clinical trials comparing palonosetron to other 5-HT(3) receptor antagonists.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19836386     DOI: 10.1016/j.ejphar.2009.10.002

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  67 in total

1.  The antiemetic 5-HT3 receptor antagonist Palonosetron inhibits substance P-mediated responses in vitro and in vivo.

Authors:  Camilo Rojas; Ying Li; Jie Zhang; Marigo Stathis; Jesse Alt; Ajit G Thomas; Sergio Cantoreggi; Silvia Sebastiani; Claudio Pietra; Barbara S Slusher
Journal:  J Pharmacol Exp Ther       Date:  2010-08-19       Impact factor: 4.030

2.  Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis.

Authors:  Gary R Morrow; Lee Schwartzberg; Sally Y Barbour; Gianluca Ballinari; Michael D Thorn; David Cox
Journal:  J Community Support Oncol       Date:  2014-07

Review 3.  Update on the management of postoperative nausea and vomiting.

Authors:  Anthony L Kovac
Journal:  Drugs       Date:  2013-09       Impact factor: 9.546

Review 4.  Postoperative vomiting in children.

Authors:  C Morrison; S Wilmshurst
Journal:  BJA Educ       Date:  2019-08-22

Review 5.  Management of Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients.

Authors:  Rudolph M Navari
Journal:  Paediatr Drugs       Date:  2017-06       Impact factor: 3.022

6.  PharmGKB summary: Ondansetron and tropisetron pathways, pharmacokinetics and pharmacodynamics.

Authors:  Rachel Huddart; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2019-06       Impact factor: 2.089

7.  Treatment of Nausea and Vomiting During Chemotherapy.

Authors:  Karen M Mustian; Katie Devine; Julie L Ryan; Michelle C Janelsins; Lisa K Sprod; Luke J Peppone; Grace D Candelario; Supriya G Mohile; Gary R Morrow
Journal:  US Oncol Hematol       Date:  2011

Review 8.  Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 9.  Chemotherapy-induced nausea and vomiting: optimizing prevention and management.

Authors:  Kamakshi V Rao; Aimee Faso
Journal:  Am Health Drug Benefits       Date:  2012-07

10.  Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia.

Authors:  Aki Matsumaru; Yutaka Tsutsumi; Shinichi Ito
Journal:  Mol Clin Oncol       Date:  2017-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.